Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study
Nutrients · 2025
DOI: 10.3390/nu17132130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Ali N Ali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2TN, UK. Hauptthemen laut MEDLINE: Carnosine, Dietary Supplements, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hestia (Czechia), Hestia Investments, Clinical Research Facility.
Abstract (Originalsprache)
Background
Carnosine is a multimodal pleotropic endogenous molecule that exhibits properties that make it a compelling therapeutic agent for further evaluation in a number of diseases. However, little data currently exists on its pharmacokinetic profile, maximum tolerated doses, side effects and whether oral administration can lead to elevated brain concentrations.
Method
To investigate this, sixteen healthy volunteers underwent a single dose-escalation study of oral carnosine to establish safety, tolerability, and pharmacokinetics. A subset (n = 5) underwent Proton Magnetic Resonance Imaging (MRI) spectroscopy to evaluate the effect of oral dosing on brain carnosine concentrations, and another subset (n = 4) completed a long-term (4-week) dosing study.
Results
Oral carnosine was safe and well tolerated up to a dose of 10 g. At doses of 15 g, the frequency of adverse events became unacceptably high, with 77% of participants experiencing side effects, most commonly headache (43.5%), nausea (21.7%) and paraesthesia (21.7%). While pharmacokinetic profiles varied between individuals, peak plasma concentrations occurred within the first hour of dosing. Little circulating carnosine was detectable beyond 4 h. Brain carnosine concentration increased at 1 h post-dose but reverted to baseline values by 5 h. Long-term dosing at 5 g twice daily did not result in any adverse events.
Conclusions
Our data will inform dosing interventions in future clinical trials of this exciting agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2TN, UK.
- Combined Community and Acute Care Group, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK.
- Department of Psychiatry, University of Cambridge, Cambridge CB2 1TN, UK.
- Biomolecular Science Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.
- Glycyx MOR, Inc., San Francisco, CA 94121, USA.
- Translational DMPK Science, Certara UK Limited, Sheffield S1 2BJ, UK.
ORCID-Profile: Ali N Ali, Jillian Newton, Amy K Grayson, David Taggart, Simon M Bell, Barbora de Courten
Förderung
- Hestia (Czechia)
- Hestia Investments
- Clinical Research Facility
- Sheffield Biomedical Research Centre, Sheffield, UK
Zitieren
APA
Ali, A. N., Su, L., Newton, J., Grayson, A. K., Taggart, D., Bell, S. M., Baig, S., Gardner, I., de Courten, B., & Majid, A. (2025). Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study. Nutrients. https://doi.org/10.3390/nu17132130
Vancouver
Ali AN, Su L, Newton J, Grayson AK, Taggart D, Bell SM, et al. Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study. Nutrients. 2025. doi:10.3390/nu17132130
BibTeX
@article{Ali2025,
author = {Ali, Ali N and Su, Li and Newton, Jillian and Grayson, Amy K and Taggart, David and Bell, Simon M and Baig, Sheharyar and Gardner, Iain and de Courten, Barbora and Majid, Arshad},
title = {Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17132130}
}
EUVIMED